Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eupraxia Pharmaceuticals Inc (EPRX.TO)

Eupraxia Pharmaceuticals Inc (EPRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 138,928
  • Shares Outstanding, K 35,623
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,221 K
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 62.69
Trade EPRX.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.17
  • Most Recent Earnings $-0.10 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.44 +8.43%
on 04/18/24
4.79 -22.13%
on 04/05/24
-0.40 (-9.69%)
since 03/26/24
3-Month
3.44 +8.43%
on 04/18/24
7.64 -51.18%
on 02/13/24
-1.47 (-28.27%)
since 01/26/24
52-Week
3.44 +8.43%
on 04/18/24
9.10 -59.01%
on 07/05/23
-2.46 (-39.74%)
since 04/26/23

Most Recent Stories

More News
Stocks in play: Eupraxia Pharmaceuticals Inc.

Announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society ...

EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.80 (-1.76%)
EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.80 (-1.76%)
EPRX.TO : 3.73 (-4.36%)
Stocks in play: Eupraxia Pharmaceuticals Inc.\

Announced today that trading of the Company's common shares will begin today, on the NASDAQ Capital ...

EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.80 (-1.76%)
EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.80 (-1.76%)
EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphereâ„¢...

EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphereâ„¢...

EPRX.TO : 3.73 (-4.36%)
Stocks in play: Eupraxia Pharmaceuticals Inc.

Has initiated its Phase 3 development program for EP-104IAR, the Company's lead drug candidate for the ...

EPRX.TO : 3.73 (-4.36%)
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphereâ„¢...

EPRX.TO : 3.73 (-4.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.

See More

Key Turning Points

3rd Resistance Point 4.00
2nd Resistance Point 3.94
1st Resistance Point 3.84
Last Price 3.73
1st Support Level 3.68
2nd Support Level 3.62
3rd Support Level 3.52

See More

52-Week High 9.10
Fibonacci 61.8% 6.94
Fibonacci 50% 6.27
Fibonacci 38.2% 5.60
Last Price 3.73
52-Week Low 3.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar